Terns Pharmaceuticals, Inc. (TERN) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending September 2025, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is held by 140 institutional firms.

• Institutional ownership in Terns Pharmaceuticals edged up to 101.7% in September 2025, compared to 91.3% in June 2025.
• In percentage terms, this reflects as a holdings change of 7.30% quarter on quarter, and a decrease of 9.09% year over year.
• A review of institutional activity for Terns Pharmaceuticals shows 66 of 140 filers increasing their positions, while 48 reduced their stake, and 26 remained unchanged.
• The aggregate institutional position in Terns Pharmaceuticals now stands at 89.01Mn shares as of September 2025, after investors increased their holdings (up by 6.05Mn shares quarter on quarter which is up 9.46Mn shares year over year).
• Soleus Capital Management, L.P.'s holding of 8.13Mn shares as of September 30, 2025 makes it the primary institutional investor in Terns Pharmaceuticals, owning 9.29% of the stock.
• Among the most significant buyers of Terns Pharmaceuticals during September 2025 were Commodore Capital LP (5.49Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.66Mn), Pictet Asset Management Holding SA (1.10Mn), Invesco Ltd. (383.14K), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (359.05K).
• Leading sellers of Terns Pharmaceuticals stock in September 2025 included CITADEL ADVISORS LLC (2.32Mn), Schonfeld Strategic Advisors LLC (1.16Mn), SUPERSTRING CAPITAL MANAGEMENT LP (497.04K), BNP PARIBAS FINANCIAL MARKETS (420.47K), STEMPOINT CAPITAL LP (359.70K).
• The top 10 institutional holders of Terns Pharmaceuticals for the quarter ending September 2025 included Soleus Capital Management, L.P. (8.13Mn), MORGAN STANLEY (7.59Mn), ORBIMED ADVISORS LLC (7.56Mn), Deep Track Capital, LP (7.50Mn), Vivo Capital, LLC (6.90Mn), Commodore Capital LP (5.70Mn), BlackRock, Inc. (5.55Mn), VANGUARD GROUP INC (4.56Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.94Mn), Candriam S.C.A. (2.37Mn).